← Back to Search

Corticosteroid and Beta Agonist

Inhaled Steroid + Beta Agonist for Pneumonia (ARREST Trial)

Phase 3
Recruiting
Led By Joe Levitt, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Chronic lung or neuromuscular disease requiring daytime oxygen or mechanical ventilation other than for obstructive sleep apnea (OSA) or obesity hypoventilation syndrome
COVID-19 positive patients receiving > 6 mg dexamethasone (40 mg prednisone equivalent dose) except for stress dose steroids for septic shock
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 7 days of randomization
Awards & highlights
Pivotal Trial

Summary

This trial will test if a combination of an inhaled corticosteroid and a beta agonist can prevent ARF in hospitalized patients with pneumonia and hypoxemia better than placebo.

Who is the study for?
Adults hospitalized with severe pneumonia and low oxygen levels who need supplemental oxygen or non-invasive ventilation can join. Excluded are those already intubated, on chronic steroids or inhaled medications for lung conditions, allergic to trial drugs, severely ill with a life expectancy under 48 hours, pregnant women, prisoners, and patients with certain heart issues.
What is being tested?
The study is testing if inhaling a mix of budesonide (a steroid) and formoterol (a beta agonist) can prevent acute respiratory failure in pneumonia patients compared to an inactive placebo. Participants will be randomly assigned to receive either the drug combination or placebo.
What are the potential side effects?
Inhaled budesonide may cause throat irritation, coughing, fungal infections in the mouth and hoarseness. Formoterol might lead to tremors, headaches, palpitations and muscle cramps. The combination could potentially increase these risks.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I need daytime oxygen or a ventilator, not just for sleep apnea or obesity breathing issues.
Select...
I am COVID-19 positive and taking more than 6 mg of dexamethasone.
Select...
I use inhaled corticosteroids or beta-agonists for my condition.
Select...
I am allergic to or cannot use inhaled corticosteroids or beta-agonists.
Select...
I am taking more than 10 mg of prednisone daily for pneumonia, not caused by COVID-19.
Select...
I take more than 10 mg of prednisone or similar daily.
Select...
I am on a breathing machine or might need one soon.
Select...
I am expected to live more than 48 hours and not stay in the hospital for over 48 hours.
Select...
I or my surrogate have not agreed to participate in the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 7 days of randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 7 days of randomization for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acute respiratory failure (ARF)

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: InterventionActive Control1 Intervention
aerosolized formoterol (20 mcg/2 ml) and budesonide (1.0 mg/2 ml) every 12 hours x 10 doses
Group II: PlaceboPlacebo Group1 Intervention
4 ml aerosolized 0.9% saline every 12 hours x 10 doses

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,471 Previous Clinical Trials
17,501,398 Total Patients Enrolled
6 Trials studying Pneumonia
117,967 Patients Enrolled for Pneumonia
National Institutes of Health (NIH)NIH
2,811 Previous Clinical Trials
8,160,638 Total Patients Enrolled
5 Trials studying Pneumonia
2,332 Patients Enrolled for Pneumonia
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,931 Previous Clinical Trials
47,766,108 Total Patients Enrolled
14 Trials studying Pneumonia
22,915 Patients Enrolled for Pneumonia

Media Library

Inhaled budesonide and formoterol (Corticosteroid and Beta Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT04193878 — Phase 3
Pneumonia Research Study Groups: Intervention, Placebo
Pneumonia Clinical Trial 2023: Inhaled budesonide and formoterol Highlights & Side Effects. Trial Name: NCT04193878 — Phase 3
Inhaled budesonide and formoterol (Corticosteroid and Beta Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04193878 — Phase 3
~69 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top